Professor Eric Van Cutsem, MD, Ph.D., is full professor and Division Head of Digestive Oncology at the University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium. In this interview, Professor Van Cutsem speaks about Comments on the DESTINY-Gastric02 trial from Enhertu.
Brief Synopsis:
Participants with stomach or gastroesophageal junction cancer will be enrolled in this trial to see if trastuzumab deruxtecan is safe and effective.
They must have stomach or gastro-esophageal junction (GEJ) cancer that is human epidermal growth factor receptor 2 (HER2) positive:
* that cannot be surgically removed
* that has spread throughout the body
* that deteriorated during or during trastuzumab treatment
A total of 80 people will be enrolled in the study. North America and the European Union will host sites.